CRISPR/cas13-medIated RNA TarGeting THerapy for the Treatment of Neovascular Age-related Macular Degeneration Investigator-initiated Trial (SIGHT-I)

Inclusion Criteria: * Males or females ≥ 50 and ≤ 80 years at the time of signing the ICF * Diagnosed of choroidal neovascularization (CNV) secondary to AMD in the study eye; * Best-corrected visual acuity (BCVA) ranged from 73 to 23 early treatment diabetic retinopathy study (ETDRS)letter score (corresponding to 20/32 to 20/320 of Snellen visual acuity) in the study eye; * BCVA in the non-study eye had an ETDRS letter score of 19(equivalent to Snellen visual acuity20/400) and above; * Able to perform visual acuity and retinal function tests and able and willing to comply with study procedures for this clinical trial; RESPONSIVE SUBJECTS: * History of need for and responsive to anti-VEGF therapy in the study eye NON-RESPONSIVE SUBJECTS: * History of receiving anti-VEGF therapy but is resistant to treatment, which is defined as: a. complete or near-complete remission of subretinal fluid after the initial 3 doses of anti-VEGF agents and thenno improvement (less than 50um reduction) or deterioration of CRT by OCT Exclusion Criteria: * Subretinal hemorrhage, scarring, or fibrosis of greater than 50% of the total lesion in the study eye; * Any condition in the Investigator's opinion that could limit visual improvement in the study eye; * Other ocular diseases that may affect central vision in the study eye (e.g., retinal vein occlusion, retinal detachment, macular hole, optic nerve disease, etc.); * Presence of CNV not due to nAMD in the study eye, * Uncontrolled glaucoma in the study eye; * Active intraocular inflammation or a history of uveitis in either eye; * History or presence of corneal dystrophy in the study eye; * Subjects with immunodeficiency diseases prone to opportunistic infections; * History of other intraocular surgery in the study eye within 3 months prior to baseline that in the Investigator's opinion could impact healing or study outcome interpretation; * Prior gene therapy or oligonucleotide therapy; * History of acute coronary syndrome, myocardial infarction, coronary revascularization, cerebrovascular accident, or transient ischemic attack within 6 months prior to the Screening Visit; * Other conditions judged by the investigator as inappropriate for the study.